



Attorney Docket No. 25158

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
WRIGHT et al.

Serial No.: 08/886,313

Group Art Unit: 1635

Filed: June 30, 1997

For: INHIBITING NEOPLASTIC CELLS UTILIZING THE RIBONUCLEOTIDE
REDUCTASE UTR

RECEIVED
JUL 14 2003
TECH CENTER 1635
USPTO

TRANSMITTAL LETTER

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:


- (1) Transmittal Letter;
- (2) Supplemental Information Disclosure Statement;
- (3) PTO Form 1449 with one (1) reference;
- (4) Check No. 18919 for \$ 180.00.

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted,

NATH & ASSOCIATES PLLC

By:


Gary M. Nath
Registration No. 26,965
Todd L. Juneau
Registration No. 40,669
Customer No. 20529

Date: July 10, 2003
NATH & ASSOCIATES PLLC
1030 15th Street NW - 6th Floor
Washington, D.C. 20005
GMN/TLJ/jnr:IDS Trans

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 10 2003

re Application of:
WRIGHT et al.

Serial No.: 08/886,313

Group Art Unit: 1635

Filed: June 30, 1997

For: INHIBITING NEOPLASTIC CELLS UTILIZING THE RIBONUCLEOTIDE
REDUCTASE UTRINFORMATION DISCLOSURE STATEMENTCommissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. §1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

[] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. §1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

[X] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311.

The enclosed statement is accompanied by [check one]:

[] i. a certification in part (e) below as specified in 37 C.F.R. §1.97(e), or

[X] ii. a check in the amount required by 37 C.F.R. §1.17(p).

[] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. §1.113, or a notice of allowance under 37 C.F.R. §1.311, but before payment of the issue fee.

[] Certification report(e) below; and

[] a check in the amount as required by §1.17(p).

[] d. The enclosed statement is being filed pursuant to 37 C.F.R. §1.97(i), for placement in the file.

[] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

#17
Plunkett
7/13/03
RECEIVED
JUL 14 2003
TECH CENTER 1600
2003
O P E
S C A 2
P A T E N T & T R A D E M A R K O F F I C E07/11/2003 MARANTEI 00000097 08886313
01 FC:1806

[] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,
or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[] Appropriate certification is attached.

[X] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[X] g. Copies of the documents are attached herewith with a completed Form PTO-1449.


or

[] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES

By: 

Gary M. Nath
Registration No. 26,965
Todd L. Juneau
Registration No. 40,669
Customer No. 20529

Date: July 16, 2003


NATH & ASSOCIATES

1030 15th Street, N.W., 6th Floor
Washington, D.C. 20005

Tel. (202) 775-8383

Fax. (202) 775-8396

GMN/TLJ/jnr: (IDS.revisedTLJ04.08.02)



FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Atty Docket 25158	Serial No. 08/886,313
Applicant WRIGHT et al.	
Filing Date June 30, 1997	Group Art Unit 1635

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
	AA	5,998,383	Dec. 7, 1999	WRIGHT et al.			Aug. 1, 1997
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

RECEIVED
JUL 14 2003
TECH CENTER 1600/2000

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Trans-lation
	AL						
	AM						
	AN						
	AO						
	AP						

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
	AT		

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP § 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.